Standard BioTools Inc. Business Acquisition, Pro Forma Revenue
Standard BioTools Inc. (LAB) reported Business Acquisition, Pro Forma Revenue of $175.08 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2025-03-11
- Standard BioTools Inc. business acquisition, pro forma revenue for the quarter ending 2024-12-31 was $46.72M, a 9.14% decline year-over-year.
- Standard BioTools Inc. business acquisition, pro forma revenue for the quarter ending 2024-09-30 was $44.97M, a 5.16% decline year-over-year.
- Standard BioTools Inc. business acquisition, pro forma revenue for the quarter ending 2024-06-30 was $37.20M, a 22.71% decline year-over-year.
- Standard BioTools Inc. business acquisition, pro forma revenue for the quarter ending 2024-03-31 was $46.19M, a 1.51% increase year-over-year.
- Standard BioTools Inc. business acquisition, pro forma revenue for fiscal 2024 was $175.08M, a 9.03% decline from fiscal 2023.
- Standard BioTools Inc. business acquisition, pro forma revenue for fiscal 2023 was $192.47M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2024-12-31 | $46.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $91.69M derived: sum of 2 quarters · filed 2025-03-11 | $128.89M derived: sum of 3 quarters · filed 2025-03-11 | $175.08M 10-K · filed 2025-03-11 |
| 2024-09-30 | $44.97M 10-Q · filed 2024-11-06 | $82.17M derived: sum of 2 quarters · filed 2024-11-06 | $128.36M 10-Q · filed 2024-11-06 | $179.78M derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-06-30 | $37.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $83.39M 10-Q · filed 2024-08-06 | $134.81M derived: sum of 3 quarters · filed 2025-03-11 | $182.22M derived: sum of 4 quarters · filed 2025-03-11 |
| 2024-03-31 | $46.19M 10-Q · filed 2024-05-09 | $97.60M derived: sum of 2 quarters · filed 2025-03-11 | $145.02M derived: sum of 3 quarters · filed 2025-03-11 | $193.15M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-12-31 | $51.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $98.83M derived: sum of 2 quarters · filed 2025-03-11 | $146.97M derived: sum of 3 quarters · filed 2025-03-11 | $192.47M 10-K · filed 2025-03-11 |
| 2023-09-30 | $47.41M 10-Q · filed 2024-11-06 | $95.55M derived: sum of 2 quarters · filed 2024-11-06 | $141.05M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $48.13M 10-Q · filed 2024-08-06 | $93.63M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $45.50M 10-Q · filed 2024-05-09 | |||
| 2014-06-30 | $27.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $57.12M 10-Q · filed 2014-08-04 | ||
| 2014-03-31 | $29.51M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |